Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenografts

Growth Factors

Volumn 31, Issue 5, 2013, Pages 154-164

  Lee, Sze Ting ^a,b   Ji, Hong ^c   Greening, David W ^c   Speirs, Robert W H ^c   Rigopoulos, Angela ^a   Pillay, Vinochani ^a   Murone, Carmel ^a   Vitali, Angela ^a   Stühler, Kai ^d   Johns, Terrance G ^a   Corner, Georgia A ^a   Mariadason, John M ^a   Simpson, Richard J ^c   Scott, Andrew M ^a,b  

^a AUSTIN HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

2D DIGE; A431; Animal model; Apoptosis; Cancer; EGFR; MAb806; Tumor microenvironment; Xenograft

Indexed keywords

COFILIN 1; DYNAMIN I; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 806; PROTEIN; PROTEIN 14 3 3; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOARCHITECTURE; DNA REPLICATION; ENDOCYTOSIS; ENERGY YIELD; FEMALE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; LIPID METABOLISM; LIQUID CHROMATOGRAPHY; METASTASIS; MOLECULAR WEIGHT; MOUSE; NICK END LABELING; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE EMS1; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; TANDEM MASS SPECTROMETRY; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885092653     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2013.824435     Document Type: Article

References (47)

1. Agnew BJ, Minamide LS, Bamburg JR. 1995. Reactivation of phosphorylated actin depolymerizing factor and identification of the regulatory site. J Biol Chem 270:17582-17587.
2. Arber S, Barbayannis FA, Hanser H, Schneider C, Stanyon CA, Bernard O, Caroni P. 1998. Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. Nature 393:805-809. (Pubitemid 28299494)
3. Arteaga CL. 2002. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 29:3-9. (Pubitemid 35191041)
4. Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D, Zhang XF. 2001. Ras activation of the Raf kinase: Tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 56: 127-155.
5. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B-Stat Methodol 57:289-300.
6. Broadie K, Rushton E, Skoulakis EM, Davis RL. 1997. Leonardo, a Drosophila 14-3-3 protein involved in learning, regulates presynaptic function. Neuron 19:391-402. (Pubitemid 27374237)
7. Burgess AW. 2008. EGFR family: Structure physiology signalling and therapeutic targets. Growth Factors 26:263-274.
8. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. 2001. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169-1176. (Pubitemid 34204207)
9. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. 2000. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. Cancer Res 60:4804-4811.
10. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, Normanno N. 2008. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214:559-567. (Pubitemid 351224199)
11. Divgi CR, Welt S, Kris M, Real FX, Yeh SD, Gralla R, Merchant B, et al. 1991. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 83:97-104.
12. Greening DW, Glenister KM, Kapp EA, Moritz RL, Sparrow RL, Lynch GW, Simpson RJ. 2008. Comparison of human plateletmembrane cytoskeletal proteins with the plasma proteome: Towards understanding the platelet-plasma nexus. Proteomics Clin Appl 2: 63-77. (Pubitemid 351210917)
13. Greening DW, Simpson RJ. 2010. A centrifugal ultrafiltration strategy for isolating the low-molecular weight (-25 K) component of human plasma proteome. J Proteomics 73:637-648.
14. Hashiguchi M, Sobue K, Paudel HK. 2000. 14-3-3zeta is an effector of tau protein phosphorylation. J Biol Chem 275:25247-25254.
15. Ji H, Moritz RL, Kim YS, Zhu HJ, Simpson RJ. 2007. Analysis of Rasinduced oncogenic transformation of NIH-3T3 cells using differentialdisplay 2-DE proteomics. Electrophoresis 28:1997-2008. (Pubitemid 47040405)
16. Ji H, Greening DW, Kapp EA, Moritz RL, Simpson RJ. 2009. Secretome-based proteomics reveals sulindac-modulated proteins released from colon cancer cells. Proteomics Clin Appl 3:433-451.
17. Johns TG, Adams TE, Cochran JR, Hall NE, Hoyne PA, Olsen MJ, Kim YS, et al. 2004. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem 279:30375-30384. (Pubitemid 38937965)
18. Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA, Perera RM, et al. 2003. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci USA 100:15871-15876. (Pubitemid 38021082)
19. Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, Scott AM, Furnari FB. 2007. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res 13:1911-1925. (Pubitemid 46952962)
20. Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK, Smyth FE, et al. 2002. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer 98:398-408. (Pubitemid 34188683)
21. Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, et al. 2003. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci USA 100: 639-644. (Pubitemid 36126105)
22. Kapoor M, Zhou Q, Otero F, Myers CA, Bates A, Belani R, Liu J, et al. 2008. Evidence for annexin II-S100A10 complex and plasmin in mobilization of cytokine activity of human TrpRS. J Biol Chem 283:2070-2077.
23. Kim S, Hwang D. 2011. Aminoacyl-tRNA synthetases and tumorigenesis: More then housekeeping. Nat Rev Cancer 11:708-718.
24. Kulkarni YM, Suarez V, Klinke 2nd DJ. 2010. Inferring predominant pathways in cellular models of breast cancer using limited sample proteomic profiling. BMC Cancer 10:291.
25. Li Z, Zhao J, Du Y, Park HR, Sun SY, Bernal-Mizrachi L, Aitken A, et al. 2008. Down-regulation of 14-3-3zeta suppresses anchorageindependent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci USA 105:162-167.
26. Liao J, Ku NO, Omary MB. 1996. Two-dimensional gel analysis of glandular keratin intermediate filament phosphorylation. Electrophoresis 17:1671-1676. (Pubitemid 26402924)
27. Lilley KS, Friedman DB. 2004. All about DIGE: Quantification technology for differential-display 2D-gel proteomics. Expert Rev Proteomics 1:401-409. (Pubitemid 43826407)
28. Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, et al. 2001. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 61: 5355-5361. (Pubitemid 32694909)
29. McNiven MA, Kim L, Kruger EW, Orth JD, Cao H, Wong TW. 2000. Regulated dynamics between dynamin and the actin-binding protein cortactin modulate cell shape. J Cell Biol 151:187-198.
30. Mendelsohn J. 2002. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20:1S-13S
31. Mi H, Thomas P. 2009. PANTHER pathway: An ontology-based pathway database coupled with data analysis tools. Methods Mol Bio 563:123-140.
32. Mi H, Lazareva-Ulitsky B, Loo R, Kejariwal A, Vandergriff J, Rabkin S, Guo N, et al. 2005. The PANTHER database of protein families, subfamilies, functions and pathways. Nucleic Acids Res 33: D284-D288. (Pubitemid 40207879)
33. Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, et al. 2001. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 61: 5349-5354. (Pubitemid 32694908)
34. Morgan A, Burgoyne RD. 1992. Interaction between protein kinase C and Exo1 (14-3-3 protein) and its relevance to exocytosis in permeabilized adrenal chromaffin cells. Biochem J 286:807-811.
35. Nicholson RI, Gee JM, Harper ME. 2001. EGFR and cancer prognosis. Eur J Cancer 37:S9-S15. (Pubitemid 32938124)
36. Niemantsverdriet M, Wagner K, Visser M, Backendorf C. 2008. Cellular functions of 14-3-3 zeta in apoptosis and cell adhesion emphasize its oncogenic character. Oncogene 27:1315-1319. (Pubitemid 351294692)
37. Olsen JV, de Godoy LM, Li G, Macek B, Mortensen P, Pesch R, Makarov A, et al. 2005. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol Cell Proteomics 4:2010-2021. (Pubitemid 41830195)
38. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H. 1997. Mitotic and G2 checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277: 1501-1505. (Pubitemid 27449237)
39. Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, et al. 2005. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 11:6390-6399. (Pubitemid 41262971)
40. Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, et al. 2007. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 104: 4071-4076. (Pubitemid 47181580)
41. Tzivion G, Gupta VS, Kaplun L, Balan V. 2006. 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 16:203-213. (Pubitemid 43810260)
42. Tzivion G, Luo ZJ, Avruch J. 2000. Calyculin A-induced vimentin phosphorylation sequesters 14-3-3 and displaces other 14-3-3 partners in vivo. J Biol Chem 275:29772-29778. (Pubitemid 32043861)
43. Unlu M, Morgan ME, Minden JS. 1997. Difference gel electrophoresis: A single gel method for detecting changes in protein extracts. Electrophoresis 18:2071-2077. (Pubitemid 27501267)
44. Wakasugi K, Slike BM, Hood J, Otani A, Ewalt KL, Friedlander M, ChereshDA, Schimmel P. 2002.Ahuman amino-acyl-tRNAsynthetase as a regulator of angiogenesis. Proc Natl Acad Sci 306:1506-1507.
45. Wells A. 1999. EGF receptor. Int J Biochem Cell Biol 31:637-643. (Pubitemid 29248872)
46. Yang N, Higuchi O, Ohashi K, Nagata K, Wada A, Kangawa K, Nishida E, Mizuno K. 1998. Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. Nature 393:809-812. (Pubitemid 28299495)
47. Zhang W, Gordon M, Lenz HJ. 2006. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann Med 38:545-551. (Pubitemid 46292021)